Our Website Uses Cookies
We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.
For more information, please contact us or consult our Privacy Notice.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
- Home
- News and Insights
- Insights
- Die strafrechtliche Rechtfertigung individueller Heilversuche und das Verhltnis von 34 StGB zu 21 Abs 2 Nr 6 AMG Topic Named Patient Use and Compassionate Use of Drugs in Germany
Die strafrechtliche Rechtfertigung individueller Heilversuche und das Verhältnis von § 34 StGB zu § 21 Abs. 2 Nr. 6 AMG (Topic: Named Patient Use and Compassionate Use of Drugs in Germany)
March 2014, Pharma Recht
February 16, 2021
FRANKFURT—WirtschaftsWoche, Germany’s leading business weekly news magazine, has named Covington as one of the “Top Law Firms” for Pharma & Medical Devices law and Dr. Dr. Adem Koyuncu a “Top Lawyer” in Germany. Dr. Dr. Koyuncu is double qualified as a lawyer and medical doctor and a partner in our Brussels and Frankfurt office. He is a chair of the firm's ...
December 7, 2016, Covington Alert
In October 2014, the Nagoya Protocol entered into force. It created a new international regulatory system affecting all life science companies that conduct R&D on biological material such as animals, seeds, flowers, viruses, fragrances, flavonoids, essential oils, enzymes, yeasts, and so on. So far, compliance by companies is progressing slowly due to ...
October 21, 2016
WASHINGTON—Covington represented India-based Piramal Enterprises and its wholly owned Critical Care subsidiary in the UK in the acquisition of five anesthesia and pain management injectable products from Janssen Pharmaceutica NV, in an all cash deal for an upfront consideration of US$155 million, and up to an additional US$20 million. The products to be acquired ...